Celnovte’s CD138(C5G6) on Automatic IHC stainer CNT360 is honored as recommendation from NordiQC

2024-01-19

By celnovte

    Share to:

Celnovte has consistently received excellent results in the international authoritative pathology quality assessment organizations—NordiQC Immunohistochemistry.

 

Last year, all antibodies submitted by Celnvote for evaluation achieved exceptional results including #HER2, #ER, #PD-L1 (TPS/CPS), #CK8/18, #PSA, #CD138, #CD5, #CD10, #MSH2, #TTF1, #p40, and #p53.

  • HER2

In this assessment, 419 laboratories participated, achieving a pass rate of 86%, with 53% rated as excellent.

  • ER

In this assessment, 440 laboratories participated, achieving a pass rate of 78%, with 22% rated as excellent.

  • PD-L1 (TPS/CPS)

In this assessment, 243 laboratories participated, achieving a pass rate of 69%, with 32% rated as excellent.

  • CK8/18

In this assessment, 282 laboratories participated, achieving a pass rate of 85%, with 65% rated as excellent.

  • PSA

In this assessment, 377 laboratories participated, achieving a pass rate of 85%, with 50% rated as excellent.

  • CD138

In this assessment, 386 laboratories participated, achieving a pass rate of 86%, with 60% rated as excellent.

  • CD5

In this assessment, 379 laboratories participated, achieving a pass rate of 72%, with 54% rated as excellent.

  • CD10

In this assessment, 403 laboratories participated, achieving a pass rate of 73%, with 48% rated as excellent.

  • MSH2

In this assessment, 350 laboratories participated, achieving a pass rate of 91%, with 62% rated as excellent.

  • TTF1

In this assessment, 401 laboratories participated, achieving a pass rate of 81%, with 71% rated as excellent.

  • p40

In this assessment, 343 laboratories participated, achieving a pass rate of 85%, with 60% rated as excellent.

  • p53

In this assessment, 372 laboratories participated, achieving a pass rate of 65%, with 29% rated as excellent.

Celnovte is commited to providing integrated pathology diagnostic solutions and better patient care!

info@celnovte.com

Related News

0